Join us on the 12th April for our live webinar! Marketing of Pharmaceutical Drugs & Interactions with Healthcare Professionals in a Digital Era.

Find out more

Meet the Team

Meet Some of the Global 80+ Professionals that Make LS Law Possible

Marisa D

Marisa D

Ethics & Compliance Director (Swiss Office)

Overview of Experience

I manage the Swiss healthcare compliance arm of Life Science Law. Based in Zug, I have over 10 years of experience working within the pharmaceutical industry as a leading several compliance projects and transparency reporting expert.

My experience includes the development of compliance strategies and culture, compliance program roll-out, risk assessments, training and polices, along with monitoring, audit and investigations, and the EFPIA reporting requirements.

Areas of Expertise

I am a pharmaceutical compliance professional. My areas of expertise within the industry includes:

  • The development and execution of compliance programs (Values and Company culture, FMV, ESG, Speak up, etc).
  • The management of risk, to include risk analysis, remediation, and monitoring.
  • The roll out of compliance management tools.
  • Fair Market Value rates.
  • EFPIA Disclosure requirements and emerging countries.
  • Trainings: creation, development, and roll out.
  • Project management E2E process expert (Transparency, CRM, Contract tool, CMS, Culture, and development, Speak up, Whistleblower, procurement, supply chain, Financial).
  • Speak up and Whistleblower project development and implementation.

 

Regulatory Bodies of Expertise

Global and local regulatory pharmaceutical Codes of practice, including EFPIA, GPRD.

Track Record

At present, I manage the E2E automation process for the EFPIA Transparency Reporting obligations for a multi-national pharmaceutical company covering the UK, Germany, Switzerland, Austria, Italy, Greece, Malta, Cyprus, Luxembourg and Belgium, Nordics, starting a new approach on emerging countries: Brazil, Argentina, Colombia and Venezuela.

I am also managing the role out of a new automated transparency reporting platform to simplify the publication in Spain, Portugal and France, and developing a new process for the payment to Patient Organizations, and Fair Market Value monitoring (FMV).